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The indirect effects of mastitis treatment are often overlooked in cost-benefit analyses, but it 
may be beneficial for the dairy industry to consider them. The cost of mastitis treatment may 
increase when the duration of intra-mammary infections are prolonged due to misdiagnosis 
of host-adapted mastitis. Laboratory diagnosis of mastitis can be costly and time consuming, 
therefore cow-side tests such as the California Milk Cell Test (CMCT) and Milk Electrical 
Resistance (MER) need to be utilised to their full potential. The aim of this study was to 
determine the relative benefit of using these two tests separately and in parallel. This was 
done using a partial-budget analysis and a cost-benefit model to estimate the benefits and 
costs  of  each  respective  test  and  the  parallel  combination  thereof.  Quarter  milk  samples 
(n = 1860) were taken from eight different dairy herds in South Africa. Milk samples were 
evaluated by means of the CMCT, hand-held MER meter and cyto-microbiological laboratory 
analysis. After determining the most appropriate cut-off points for the two cow-side tests, 
the sensitivity and specificity of the CMCT (Se = 1.00, Sp = 0.66), MER (Se = 0.92, Sp = 0.62) 
and the tests done in parallel (Se = 1.00, Sp = 0.87) were calculated. The input data that were 
used for partial-budget analysis and in the cost-benefit model were based on South African 
figures at the time of the study, and on literature. The total estimated financial benefit of 
correct diagnosis of host-adapted mastitis per cow for the CMCT, MER and the tests done in 
parallel was R898.73, R518.70 and R1064.67 respectively. This involved taking the expected 
benefit of a correct test result per cow, the expected cost of an error per cow and the cost of the 
test into account. The CMCT was shown to be 11% more beneficial than the MER test, whilst 
using the tests in parallel was shown to be the most beneficial method for evaluating the 
mastitis-control programme. Therefore, it is recommended that the combined tests should be 
used strategically in practice to monitor udder health and promote a pro-active udder health 
approach when dealing with host-adapted pathogens.
Introduction
When mastitis, due to host-adapted pathogens Staphylococcus aureus (S. aureus) and Streptococcus 
agalactiae, (S. agalactiae) is misdiagnosed, the risk of more severe udder parenchymal damage 
increases. Longer periods of bacterial infection and shedding can create a prolonged window of 
opportunity for clinical mastitis to develop and for contagious transmission to occur (Lam 1996; 
Zadocks et al. 2002). In addition to dry-cow treatment, treatment of clinical mastitis forms part of 
most mastitis-control programmes (Swinkels, Hogeveen & Zadocks 2005). 
Staphylococcus aureus mastitis is highly prevalent in South African dairy herds and is a costly 
disease (Petzer et al. 2009). According to Goodger and Ferguson 1987 and Zepeda et al. 1998, 
control of S. aureus mastitis through preventive measures, early detection, dry-cow treatment and 
culling of chronically infected animals can be economically profitable. 
Determining the costs specific to a single disease-control programme requires partial budgeting 
(Smith 1995). In this study, partial-budget analysis was used to determine the relative effects of 
diagnosing and misdiagnosing true positive and true negative animals. These results were then 
used to perform a cost-benefit analysis.
In this study, the gold standard used for mastitis diagnosis was defined as a somatic cell count 
(SCC) of ≥ 400 000 cells/mL milk and the presence of mastitogenic bacteria (Petzer et al. 2009). 
Chronic mastitis, which is associated with a low probability of cure, may be diagnosed by clinical 
signs. These include palpable tissue changes, a history of repeated clinical mastitis, the presence 
of bacteria and infection of multiple quarters within a cow (Sol et al. 1997; Sol et al. 2000; Deluyker, 
Van Oye & Boucher 2005).
Cow-side tests, such as the California Milk Cell Test (CMCT) and Milk Electrical Resistance 
(MER) are relatively cost effective and are used in the milking parlour for timeous identification 
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of  possible  udder  health  problems  as  part  of  a  mastitis-
control programme. The International Dairy Federation (IDF) 
requirement for a cow-side test is for it to have a sensitivity of 
at least 70% and a specificity of 99% (Mein 2010). 
The purpose of this study was to determine the most beneficial 
cut-off points for the diagnosis of mastitis using either of the 
cow-side tests, when compared to the gold standard. This 
was done for tests used both separately and in a parallel 
combination. These cut-off points were then used to calculate 
sensitivity and specificity. Earlier identification of mastitis 
using  cow-side  tests  is  more  beneficial  to  producers  in  a 
mastitis-control programme and could provide the producer 
with  valuable  information  regarding  the  early  treatment 
of  true  mastitis  cases.  This  approach  supports  proactive 
udder-health management and may assist in the reduction 
of the mammary infection rate in herds. Indirect effects of 
mastitis treatment, such as prevention of clinical mastitis and 
transmission of infections to other cows are often overlooked 
in cost-benefit analysis, which may indicate that treatment 
is more favourable (St Rose et al. 2003; Swinkels et al. 2005).
Methods
Sample collection
The order in which the tests were performed in the parlour 
was  as  follows:  a  strip  cup  was  used  to  identify  possible 
clinical  mastitis  cases,  after  which  aseptic  quarter  milk 
samples were taken, followed by quarter MER readings and 
the CMCT. 
Quarter milk samples (n = 1860) were collected aseptically 
according  to  standard  procedure  (Giesecke,  Du  Preez  & 
Petzer 1994) from eight dairies in South Africa. These samples 
were placed on ice and transported to the Milk Laboratory, 
Production  Animal  Studies,  Onderstepoort  and  were 
analysed  within  12  hours  of  collection.  Following  aseptic 
sampling, approximately 5 mL milk from each quarter was 
milked  into  the  handheld  MER  meter.  The  reading  was 
recorded and this milk was poured into the corresponding 
cup  of  the  CMCT  spatula,  in  order  for  the  CMCT  to  be 
performed. This process was repeated for each quarter that 
was sampled. 
Milk electrical resistance (MER)
Electrical resistance, the reciprocal of electrical conductivity, 
was measured in this study. Hand-held MER meters were 
used to evaluate udder health on a quarter basis. This is in 
contrast to in-line conductivity that is used in commercial 
dairies, which is measured at cow level. The hand-held MER 
meters  (Mast-O-Test,  Durotec,  PO  Box  12540,  Centralhill, 
Port Elizabeth 6006, South Africa) read electrical resistance in 
milli-Ohms per centimeter (mΩ/cm). Measures of resistance 
were categorised into three ordinal levels for data analysis, 
< 24 mΩ/cm (red light), 24 – 31 mΩ/cm (orange light) and 
>  31  mΩ/cm  (green  light),  based  on  the  manufacturer’s 
suggestion. An inter-quarter variation in resistance of 15% 
or more indicated possible udder health problems (Mast-O-
Test, Durotec, PO Box 12540, Centralhill, Port Elizabeth 6006, 
South Africa). 
California Milk Cell Test (CMCT)
The CMCT spatulas were pre-calibrated to help ensure that 
equal volumes of milk and reagent were used in each test 
(Schalm,  Carroll  &  Jain  1971).  Excess  milk  was  carefully 
discarded up to the calibration line, ensuring that the volume 
of milk left in each cup was equal to the volume of reagent 
to be added. The milk and reagent were thoroughly mixed 
whilst carefully studying the viscosity of the mixtures. In this 
study, the same operator performed the reading according 
to  the  description  of  Schalm  et  al.  1971.  A  weak  positive 
(+) was recorded if during swirling, the mixture remained 
liquid (as with a negative score) and on tilting the paddle, 
the mixture flowed over the bottom of the cup in a slimy, 
streaky layer that was clearly visible. A distinct positive (++) 
was recorded if after the first one to two swirls of the mixture 
there was already distinct gel formation. Some portions of 
the distinct positive mixture tended to collect at the centre 
of  the  cup,  whereas  others  continued  to  move  around  its 
periphery. Upon stopping the swirling motion, the gel-like 
mixture  levelled  out  to  cover  the  bottom  evenly  and  on 
tilting the paddle, the mixture flowed over the bottom of 
the cup in a distinctly slimy non-uniform mass, possibly of 
streaky appearance. A strong positive (+++) was recorded 
if after the first one to two swirls the mixture had already 
formed a jelly that tended to adhere to the centre of the cup, 
where it formed a peak and left the periphery of the bottom 
of the cup exposed. After stopping the swirling motion, the 
mixture levelled out somewhat on the bottom of the cup, but 
its surface remained uneven and continued to show a distinct 
peak in its central region (Schalm et al. 1971).
Acid milk is indicated by the mixture becoming distinctly 
yellow, with a pH 5.2. This is very rare and usually indicates 
fermentation of lactose by bacteria. Alkaline milk is indicated 
when  the  reaction  causes  the  mixture  to  become  a  deep 
purple colour, it may be as a result of udder inflammation 
or indicating that the udder is drying off (Schalm et al. 1971).
Laboratory procedures
Samples were plated out onto Columbia Agar base plates with 
5%  defibrinated  bovine  blood  (Quantum  Biotechnologies 
(Pty)  Ltd,  Ferndale,  South  Africa).  Test  plates  were 
incubated for 24 to 48 hours at 37°C ± 1°C. Isolated bacteria 
were  identified  in  accordance  with  standard  laboratory 
milk  culture  methodology  based  on  colony  morphology, 
haemolysis, catalase, KOH test and Gram staining. Additional 
tests  for  bacterial  identification  included  a  Strepkit  (Latex 
agglutination  test  from  Quantum  Biotechnologies  (Pty) 
Ltd,  Ferndale,  South  Africa),  Staphylase  Test  (Quantum 
Biotechnologies (Pty) Ltd, Ferndale, South Africa) and the 
API  20E  kit  (BioMerieux,  PO  Box  4328,  Honeydew  2040) 
(Sandholm  et  al.  1995;  Karzis  2005).  SCC  was  determined 
using  the  Fossomatic  5000  (Rhine  Rhur,  PO  Box  76167, 
Wendywood 2144). 
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Analysis of data: Sensitivity, Specificity and 
Determination of Cut-off points
Data was collected from 1860 aseptic quarter milk samples 
from eight different dairy herds in South Africa. This data 
was analysed using a gold standard (criteria used for mastitis 
positive quarters were: SCC ≥ 400 000 cells/mL and bacteria 
present). Then the most appropriate cut-off point for each 
test was determined using the gold standard in the statistical 
programme  GenStat®  (Payne  et  al.  2011).  Using  these  cut-
off points, the sensitivity and specificity of each of the tests 
was calculated from the data using Microsoft Excel® 2003. 
The criteria of the gold standard used for disease positive 
quarters (SCC ≥ 400 000 cells/mL) with bacteria present was 
taken into account for each test done separately and for both 
tests done in parallel (Dohoo, Martin & Stryhm 2003; Petzer 
et al. 2009).
These findings were used as criteria to determine whether 
each quarter had an increased SCC using the CMCT, with 
(1+,  2+  and  3+)  indicating  a  positive  test  result  and  (0) 
indicating a negative test result. Increased SCC, as well as 
udder inflammation, are an indication of a possible mastitis 
case in a mastitis-control programme.
Similarly, the criteria used to evaluate udder inflammation 
of  quarters  using  MER  were  as  follows:  an  orange  light 
(24  –  31  mΩ/cm)  and  red  light  (<  24  mΩ/cm)  indicated 
a  positive  test  result,  whilst  a  green  light  (>  31  mΩ/cm) 
indicated  a  negative  test  result;  the  latter  being  a  healthy 
quarter.  Both  sets  of  criteria  were  calculated  in  GenStat® 
using the gold standard (as described above).
The sensitivity and specificity of each of the tests and of the 
tests in parallel were then inserted into the model as inputs.
Modelling approach 
Partial-budget  analysis  was  used  as  part  of  a  cost-benefit 
model. In a cost-benefit model, economic effects for any given 
scenario  are  calculated  as  total  revenues  weighed  against 
total costs. In this model, the expected cost or benefit of a 
specific test was calculated. This was done by determining 
the  likelihood  that  a  specific  test  would  predict  a  false 
positive, false negative, true positive or true negative result. 
An expected cost or benefit was associated with each of these 
outcomes. For example, correctly identifying a true positive 
result and acting on it would have certain benefits, such as a 
reduction in the infection rate and a reduction in the decline 
of milk yield and milk quality. It also has costs associated, 
such as the cost of treatment and the cost of additional labour. 
Similarly,  incorrectly  identifying  a  true  negative  result  as 
positive would have costs associated, such as an increase in 
the loss of milk, an increase in antibiotic residues present in 
milk and in the bulk tank due to unnecessary treatment, and 
the cost of treatment. 
Partial-budget  analysis  was  used  to  calculate  the  relative 
costs  and  benefits.  In  partial-budget  analysis,  alternatives 
are  compared  without  calculating  a  complete  budget  for 
each scenario. Instead, only the revenues and costs that are 
affected by the specific scenario are considered. Total returns 
were calculated as extra returns plus reduced costs. Total 
costs were calculated as reduced returns plus extra costs. Both 
direct and indirect effects of diagnosing and misdiagnosing 
true  positive  and  true  negative  animals  were  taken  into 
account. Biological parameters included the clinical outcome 
of  infection  with  host  adapted  pathogens  for  the  affected 
animal, effects at herd level and contagious transmission for 
true positives (detected and undetected).
The sensitivity and specificity for each test were used in the 
cost-benefit model as a basis for determining the expected 
costs and benefits of each test. The expected value of each 
cost  or  benefit  was  calculated  by  determining,  from  the 
sensitivity  and  specificity  of  each  test,  the  positive  and 
negative predictive values of each test. The expected value of 
a true positive outcome was calculated as the probability of 
a test identifying a true positive case multiplied by the cost 
or benefit of that outcome, and similarly for other outcomes. 
Costs  and  benefits  of  correct  or  incorrect  diagnoses  were 
calculated at the cow level (Swinkels et al. 2005). 
This  model  was  applied  separately  for  each  of  the  two 
cow-side tests, as well as for tests used in parallel in order 
to determine which of the methods were more beneficial, 
compared to the gold standard criteria used. A comparison 
of the value of benefits that could be expected from a given 
test, based on the cost-benefit model, was used to estimate the 
value of the mastitis-control programme, using the CMCT 
test,  the  MER  test  or  a  combination  thereof  (Smith  1995). 
Model input variables were based on current South African 
economic conditions and on literature (Keefe 1997; Lactodata 
2011). The accuracy of the mastitis- control programme in 
correct diagnosis of mastitis using the CMCT, MER and the 
tests in parallel was compared to the gold standard used. 
Statistical  analysis  was  performed  using  Microsoft  Excel® 
2003, by taking the model inputs and prices calculated (see 
below) into account (Dohoo et al. 2003).
Prices used for model inputs
Cost of treatment (R45.45) was calculated using the cost of 
Curaclox LC (Norbrook (ARK AH) PO Box 10698, Centurion 
0046), which is commonly used (R15.15 per treatment x three 
treatments). Milk loss as a result of treatment (R360.86) was 
calculated  using  the  current  milk  price  at  the  time  of  the 
investigation (R2.97/L) x the average milk production per 
cow per day (27 L) (Lactodata 2011) x the number of days for 
which milk was discarded (4.5 days). This was calculated as 
the sum of the three treatments of Curaclox LC (Norbrook 
(ARK  AH)  PO  Box  10698,  Centurion  0046)  at  12  hourly 
intervals (1.5 days) and the (72h or three day) withdrawal 
period of the product after final infusion, for which milk was 
discarded. Original Research
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The cost of CMCT test was calculated by calculating the costs 
of the following:
Mastest  reagent  per  test  =  price  of  Mastest  per  5  L  (R490)/
number of tests per 5 L (888.33) = 0.55
Number of 6mL CMCT tests done per 5 L = (1000 mL/6 mL per 
test = 166.66 tests) x 5 L = 888.33
The cost of the CMCT paddle = R60/number of tests per 5 L 
(R888.33) = R0.068
Pump bottle = R30/number of tests per 5 L (R888.33) = R0.034 
Marking pen = R20/number of tests per 5 L (R888.33) = R0.023 
The cost of the CMCT per cow (R2.70) was calculated using 
the sum of the cost of Mastest reagent per CMCT (R0.55), 
the cost of the CMCT paddle (R0.068) per test, the cost of the 
pump bottle (R0.034) per test and the cost of the marking pen 
(R0.023) used for calibration per test x four quarters per cow.
The  cost  of  the  MER  test  per  cow  (R5.36)  was  calculated 
by the sum of the cost of the handheld Mast-O-Test meter 
(R2500/1860 tests = R1.34 per test) (Csi-Africa 2011, product 
specifications) x four quarters.
Cost-benefit model inputs 
For each test, the cost and benefit of each possible test outcome 
was calculated. For each possible outcome, positive effects 
were calculated as benefits and negative effects as costs. For 
all calculations, the cost of performing the test was included. 
This model was calculated over the 305 day lactation period 
for cows infected with host-adapted organisms (Keefe 1997). 
The following four scenarios were analysed for CMCT, MER 
and using the tests in parallel. 
True positive cases (Sensitivity)
The benefit of detecting true positive cases of mastitis with 
cow-side tests was calculated as follows:
(Culling  cost  (R6000)  x  13%  reduced  infection  rate  [19])  + 
reduced loss of milk (R360.86) – treatment cost (R45.45 x 87%) 
[19] = R1101.32 (Table 1)
False negative cases
The cost of not detecting true positive cases of mastitis by the 
cow-side tests was calculated as follows:
Estimated loss of milk yield due to sub-clinical mastitis (R360.86) 
x 13% increased infection rate [19] = R46.91
True negative cases (Specificity)
The detection of a quarter with normal udder health by the 
test is beneficial and has no cost implications.
False positive cases
The cost of misdiagnosing a healthy quarter with the test was 
calculated as follows:
The cost of unnecessary treatment (R45.45) + the consequent loss 
of milk (R360.86) = R406.31
For a given outcome, the expected benefit of the outcome 
was  calculated  by  multiplying  the  net  benefit  with  the 
likelihood of attaining the outcome (i.e. false positive, false 
negative, true positive, true negative) through the use of this 
test. The overall cost of the test per cow was subtracted from 
the expected benefit for all scenarios, since a test is always 
conducted.
Benefit-cost ratios
Benefit-cost ratios were calculated as follows (for each test 
done separately and for both tests combined):
Benefit-cost ratios = expected benefit or (expected cost of error 
+ cost of test).
Results and discussion
Long  periods  of  infection  and  bacterial  shedding  due  to 
misdiagnosis create a prolonged window of opportunity for 
clinical mastitis to develop and for contagious transmission 
to  occur.  In  addition  to  dry-cow  treatment,  treatment  of 
clinical mastitis is part of most mastitis-control programmes. 
Indirect effects of mastitis treatment, such as prevention of 
TABLE 1: A partial-budget analysis using a cost-benefit model to estimate benefits and costs of the CMCT, MER test done separately and in parallel. 
Tests Cost-benefit Model 
Inputs
Probability Cost of incorrect diagnosis  Benefit of correct diagnosis
Cost of test 
per cow
Expected cost of 
error per cow
Benefit of test 
per cow 
Expected benefit of 
test per cow
CMCT Sensitivity 1.00 - - R1101.32 R1101.32
False negative - R46.91 - - -
Specificity 0.66 - - R406.31 R268.17
False positive 0.34 R406.31 R138.15 - -
Total - - R138.15 - R1369.48
MER Sensitivity 0.92 - - R1101.32 R1013.21
False negative 0.08 R46.91 R3.75 - -
Specificity 0.62 - - R406.31 R251.91
False positive 0.38 R406.31 R154.33 - -
Total - - R158.08 - R1265.12
CMCT & MER in 
parallel
Sensitivity 1.00 - - R1101.32 R1101.32
False negative - R46.91 - - -
Specificity 0.87 - - R406.31 R353.81
False positive 0.13 R406.31 R52.50 - -
Total - - R52.50 - R1455.13
CMCT, California Milk Cell Test, MER, Milk Electrical Resistance.Original Research
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repeated clinical mastitis and transmission to other cows, are 
often overlooked in cost-benefit analysis, but render a specific 
treatment as being more favourable (Waage & Aursjoe 1993; 
Lam 1996; Hamman & Zecconi 1998; Zadoks et al. 2002; St 
Rose et al. 2003; Swinkels et al. 2005). 
The  sensitivity  of  CMCT  and  the  parallel  combination 
of CMCT and MER tests are both equal to 1, proving that 
these methods of diagnosis are equally able to identify true 
positive animals in the mastitis-control programme, with the 
expected benefit of test per cow being R1101.32 (Table 1). This 
is a surprising result, as it was expected that the combination 
of the two tests (measuring two mastitis indicators) should 
have had an advantage over one test (measuring only one 
mastitis indicator). The sensitivity of the MER test of 0.92 
(Table  1),  show  that  it  is  slightly  less  able  to  detect  true 
positive animals in the mastitis-control programme than the 
CMCT test or the tests done in parallel. 
The  specificity  of  CMCT,  MER  test  and  the  tests  done  in 
parallel  were  0.66,  0.62  and  0.87  respectively  (Table  1), 
indicating  that  the  tests  done  in  parallel  were  the  most 
beneficial for detecting true negative animals. It also indicated 
that the CMCT was more beneficial than the MER test for 
the  same  purpose.  The  probability  of  diagnosing  a  false 
negative case using the CMCT and the tests done in parallel 
were 0, indicating that these methods were more beneficial in 
mastitis diagnosis than the MER test (p = 0.08) (Table 1), with 
the cost of error per cow being estimated at R46.91 (Table 1). 
The probability of a false positive case using the MER test 
was higher than both that of CMCT on its own and the tests 
done in parallel, indicating that the MER test was more likely 
to misdiagnose true negative animals, with the cost of error 
per cow being estimated at R406.31 (Table 1).
Partial-budget analysis was used in order to estimate benefits 
and  costs  to  producers  of  a  mastitis-control  programme. 
The  part  of  the  enterprise  budget  affected  by  mastitis 
was separated out so that the effects of mastitis were not 
overshadowed by some other factor or disease (Smith 1995).
A cost-benefit model was used as a method for calculating 
the cost-benefit ratio, which was an index of the rand value 
of benefits that could be expected from an investment with a 
given cost associated (Smith 1995).
The  cost-benefit  model  was  also  used  to  calculate  the 
expected costs and benefits of a specific scenario. The sum of 
the total expected cost of errors per cow (Table 1) and the cost 
to conduct the test per cow (Table 2) was subtracted from the 
expected benefits of test per cow for CMCT, MER test. The 
tests were performed in parallel in order to calculate the total 
expected benefit of the tests (Table 1). 
The CMCT was shown to be more beneficial than the MER 
test, with a total expected benefit of test per cow of R1228.64 
as opposed to that of R1100.29 (Table 2). The most beneficial 
method  for  diagnosing  mastitis  in  the  mastitis-control 
programme was using both cow-side tests in parallel, with 
a total expected benefit of test per cow of R1393.25 (Table 1). 
The conclusions made in this study were consistently made 
on the evaluation of an expected benefit. However, benefit-
cost ratios were calculated as being 9.72 for CMCT, 7.74 for 
MER and 24.02 for both tests in parallel (see Table 2). 
Conclusions
The gold standard used for mastitis diagnosis in this study 
was  a  SCC  ≥  400  000  cells/mL  milk  and  the  presence  of 
pathogens  (Petzer  et  al.  2009),  which  can  be  both  costly 
and  time  consuming.  A  cost-benefit  model  was  used  to 
estimate the accuracy of the mastitis-control programme, by 
comparing the costs and benefits that arise from using the 
CMCT, MER test, or both tests in parallel. Misdiagnosis of 
true mastitis cases by cow-side tests increases the duration of 
infection when treatment of mastitis is postponed. 
When used separately, the expected benefit of CMCT is 11% 
more beneficial than the MER test in diagnosing mastitis. The 
cost-benefit model indicates that, by using the CMCT and 
MER tests in parallel, the total expected benefit of test per 
cow is the highest and the expected cost of error per cow the 
lowest. The total expected benefit of both tests in parallel is 
13% more than that of the MER alone, and 11% more than 
that of the CMCT alone.
The sensitivity and specificity for the CMCT test is higher 
than that of the MER test and similar to that of the two cow-
side tests used in parallel. The cost-benefit ratio of using both 
tests in parallel is 2.5 times that of the CMCT test alone, and 
3.1 times that of the MER test alone. With all parameters 
considered, and taking all costs and benefits into account it is 
clearly beneficial to use both test in parallel.
Further  research  is  recommended  to  analyse  the  data 
collected  from  in-line  EC  meters  based  on  cow  samples, 
comparing the accuracy of the results to CMCT results and a 
combination thereof against the gold standard. Future work 
with respect to modelling and sensitivity analysis is required 
in order to assess the extent of reduction in infection rates 
that should be maintained by control programmes in order 
to ensure that the process of testing and control of yield has a 
financially viable outcome.
TABLE  2:  Summary  of  the  cost-benefit  model  showing  expected  costs  and 
benefits and the cost-benefit ratio of the CMCT and MER test done separately 
and in parallel, taking cost of test per cow into account.
Summary  CMCT MER Tests done in 
parallel
Expected benefit of test 
per cow
R1369.48 R1265.12 R1455.13
Expected cost of error 
per cow
- R138.15 - R158.15 - R52.50
Cost to conduct test 
per cow
- R2.70 - R5.38 - R8.08
Cost-benefit ratio 9.72 7.74 24.02
Total expected benefit 
of test per cow
R1228.64 R1100.29 R1393.25
CMCT, California Milk Cell Test, MER, Milk Electrical Resistance.Original Research
doi:10.4102/ojvr.v80i1.538 http://www.ojvr.org
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